Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck in Supply Agreement With Canada for Antiviral Medicine for Covid-19

12/03/2021 | 02:45pm EST

By Michael Dabaie

Merck & Co. Inc. said it is in a supply agreement with the Canadian government for up to 1 million patient courses of molnupiravir, its investigational oral antiviral medicine for the treatment of Covid-19.

Merck is developing molnupiravir in collaboration with Ridgeback Biotherapeutics.

The government of Canada secured access in 2022 to 500,000 patient courses, with options for up to 500,000 more, pending Health Canada approval.

In November, Merck Canada filed the final wave of the molnupiravir rolling submission to Health Canada, which will decide on the therapy's approval when all necessary evidence has been reviewed.

The U.S. Food and Drug Administration's Antimicrobial Drugs Advisory Committee recently voted 13-10 that the known and potential benefits of molnupiravir outweigh its known and potential risks for the treatment of mild to moderate Covid-19 in high-risk adult patients. While the FDA isn't bound by the committee's guidance, it takes that advice into consideration.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

12-03-21 1445ET

All news about MERCK & CO., INC.
08:00aMerck & Co. To Supply 3 Million Doses Of COVID-19 Drug To UNICEF
07:37aMerck, Ridgeback Biotherapeutics to Supply 3 Million Courses of COVID-19 Pill to UNICEF
06:46aMerck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investig..
02:44aECO Animal Health Group CEO Retires, Successor Named
01/14Pfizer Reportedly Seeks Japan Approval for COVID-19 Pill
01/14Merck's COVID-19 Pill Molnupiravir Gets Emergency Approval in Indonesia
01/12I-Mab Doses First Phase 2 Clinical Trial of Efineptakin Alfa, Keyrtruda Combination in ..
01/12IMV Doses First Patient in Study for Lymphoma Treatment
01/11Aligos Therapeutics Shares Rise 6% on Merck Collaboration Agreement
01/11GLOBAL MARKETS LIVE : Airbus, Nokia, Pandora, Darktrace, Amazon...
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 48 687 M - -
Net income 2021 11 938 M - -
Net Debt 2021 17 019 M - -
P/E ratio 2021 17,4x
Yield 2021 3,21%
Capitalization 206 B 206 B -
EV / Sales 2021 4,57x
EV / Sales 2022 3,85x
Nbr of Employees 73 500
Free-Float -
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 81,38 $
Average target price 92,27 $
Spread / Average Target 13,4%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.6.18%205 561
JOHNSON & JOHNSON-1.89%441 855
ROCHE HOLDING AG-3.10%325 363
PFIZER, INC.-6.94%308 427
ABBVIE INC.0.35%240 202
NOVO NORDISK A/S-15.01%223 075